{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:20:03Z","timestamp":1788877203322,"version":"build-2803163510"},"reference-count":133,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100003607","name":"Association for Frontotemporal Degeneration","doi-asserted-by":"publisher","award":["Pilot#2025-002"],"award-info":[{"award-number":["Pilot#2025-002"]}],"id":[{"id":"10.13039\/100003607","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Alzheimer's Association,United States","award":["24AACSFD-1244095"],"award-info":[{"award-number":["24AACSFD-1244095"]}]},{"DOI":"10.13039\/100008539","name":"CurePSP","doi-asserted-by":"publisher","award":["684-2023-06-Pathway"],"award-info":[{"award-number":["684-2023-06-Pathway"]}],"id":[{"id":"10.13039\/100008539","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"DOI":"10.1007\/s11910-026-01488-0","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T08:09:09Z","timestamp":1774426149000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Amyloid and Tau Co-pathology in Parkinson Disease and Atypical Parkinsonism"],"prefix":"10.1007","volume":"26","author":[{"given":"Maria Jose","family":"Angel Pinto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indira","family":"Garc\u00eda Cordero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Dorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Mizraji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Anastassiadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Gershanik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blas","family":"Couto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"issue":"10","key":"1488_CR1","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1001\/jamaneurol.2020.1741","volume":"77","author":"S Karanth","year":"2020","unstructured":"Karanth S, et al. Prevalence and Clinical Phenotype of Quadruple Misfolded Proteins in Older Adults. JAMA Neurol. 2020;77(10):1299\u2013307.","journal-title":"JAMA Neurol"},{"issue":"1","key":"1488_CR2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/ana.26930","volume":"96","author":"I Garcia-Cordero","year":"2024","unstructured":"Garcia-Cordero I, et al. Evaluating the Effect of Alzheimer\u2019s Disease-Related Biomarker Change in Corticobasal Syndrome and Progressive Supranuclear Palsy. Ann Neurol. 2024;96(1):99\u2013109.","journal-title":"Ann Neurol"},{"issue":"7","key":"1488_CR3","doi-asserted-by":"publisher","first-page":"4765","DOI":"10.1002\/alz.13914","volume":"20","author":"NA Singh","year":"2024","unstructured":"Singh NA, et al. Relationships between PET and blood plasma biomarkers in corticobasal syndrome. Alzheimers Dement. 2024;20(7):4765\u201374.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1488_CR4","first-page":"e207901","volume":"102","author":"C Palleis","year":"2024","unstructured":"Palleis C, et al. Association Neurofilament Light Chain [Neurology. 2024;102(1):e207901.","journal-title":"Association Neurofilament Light Chain [Neurology"},{"issue":"1","key":"1488_CR5","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3233\/JAD-190961","volume":"74","author":"A Benvenutto","year":"2020","unstructured":"Benvenutto A, et al. Clinical Phenotypes in Corticobasal Syndrome with or without Amyloidosis Biomarkers. J Alzheimers Dis. 2020;74(1):331\u201343.","journal-title":"J Alzheimers Dis"},{"key":"1488_CR6","doi-asserted-by":"publisher","first-page":"737195","DOI":"10.3389\/fneur.2021.737195","volume":"12","author":"K Malfertheiner","year":"2021","unstructured":"Malfertheiner K, Stefanova N, Heras-Garvin A. The Concept of \u03b1-Synuclein Strains and How Different Conformations May Explain Distinct Neurodegenerative Disorders. Front Neurol. 2021;12:737195.","journal-title":"Front Neurol"},{"issue":"1","key":"1488_CR7","doi-asserted-by":"publisher","first-page":"19423","DOI":"10.1038\/s41598-020-76565-6","volume":"10","author":"K Araki","year":"2020","unstructured":"Araki K, et al. The secondary structural difference between Lewy body and glial cytoplasmic inclusion in autopsy brain with synchrotron FTIR micro-spectroscopy. Sci Rep. 2020;10(1):19423.","journal-title":"Sci Rep"},{"key":"1488_CR8","doi-asserted-by":"publisher","first-page":"552","DOI":"10.3389\/fnins.2019.00552","volume":"13","author":"J Ma","year":"2019","unstructured":"Ma J, et al. Prion-Like Mechanisms in Parkinson\u2019s Disease. Front Neurosci. 2019;13:552.","journal-title":"Front Neurosci"},{"key":"1488_CR9","doi-asserted-by":"publisher","unstructured":"Graves NJ, Gambin Y, Sierecki E. \u03b1-Synuclein Strains and Their Relevance to Parkinson\u2019s Disease, Multiple System Atrophy, and Dementia with Lewy Bodies. Int J Mol Sci, 2023. 24(15). https:\/\/doi.org\/10.3390\/ijms241512134","DOI":"10.3390\/ijms241512134"},{"key":"1488_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13024-015-0025-8","volume":"10","author":"ML Caillet-Boudin","year":"2015","unstructured":"Caillet-Boudin ML, et al. Regulation of human MAPT gene expression. Mol Neurodegener. 2015;10:28.","journal-title":"Mol Neurodegener"},{"issue":"3","key":"1488_CR11","doi-asserted-by":"publisher","first-page":"4671","DOI":"10.3390\/ijms15034671","volume":"15","author":"A Mietelska-Porowska","year":"2014","unstructured":"Mietelska-Porowska A, et al. Tau protein modifications and interactions: their role in function and dysfunction. Int J Mol Sci. 2014;15(3):4671\u2013713.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"1488_CR12","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41582-021-00541-5","volume":"17","author":"M Stamelou","year":"2021","unstructured":"Stamelou M, et al. Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies. Nat Rev Neurol. 2021;17(10):601\u201320.","journal-title":"Nat Rev Neurol"},{"issue":"7","key":"1488_CR13","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/s41374-019-0197-x","volume":"99","author":"KH Strang","year":"2019","unstructured":"Strang, K. H., Golde, T. E., & Giasson, B. I. (2019). MAPT mutations, tauopathy, and mechanisms of neurodegeneration. Laboratory Investigation, 99(7), 912\u201328.","journal-title":"Laboratory Investigation"},{"issue":"4","key":"1488_CR14","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1001\/jamaneurol.2019.4749","volume":"77","author":"PF Meyer","year":"2020","unstructured":"Meyer PF, et al. Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography. JAMA Neurol. 2020;77(4):508\u201316.","journal-title":"JAMA Neurol"},{"issue":"3","key":"1488_CR15","doi-asserted-by":"publisher","first-page":"e70038","DOI":"10.1002\/alz.70038","volume":"21","author":"J Wang","year":"2025","unstructured":"Wang J, et al. Diagnostic accuracy of plasma p-tau217\/A\u03b242 for Alzheimer\u2019s disease in clinical and community cohorts. Alzheimers Dement. 2025;21(3):e70038.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"1488_CR16","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"1488_CR17","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41582-025-01091-w","volume":"21","author":"CE Teunissen","year":"2025","unstructured":"Teunissen, C. E., & Vermunt, L. (2025). Implications of AD plasma and PET biomarker discordance. Nature Reviews Neurology, 21(6), 295\u20136.","journal-title":"Nature Reviews Neurology"},{"issue":"1","key":"1488_CR18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40035-024-00449-2","volume":"13","author":"Y Kuang","year":"2024","unstructured":"Kuang Y, et al. \u03b1-Synuclein seeding amplification assays for diagnosing synucleinopathies: an innovative tool in clinical implementation. Transl Neurodegener. 2024;13(1):56.","journal-title":"Transl Neurodegener"},{"issue":"11","key":"1488_CR19","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1001\/jamaneurol.2024.3162","volume":"81","author":"I Martinez-Valbuena","year":"2024","unstructured":"Martinez-Valbuena I, et al. Four-Repeat Tau Seeding in the Skin of Patients With Progressive Supranuclear Palsy. JAMA Neurol. 2024;81(11):1228\u201330.\u00a0https:\/\/doi.org\/10.1001\/jamaneurol.2024.3162","journal-title":"JAMA Neurol"},{"issue":"3","key":"1488_CR20","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/mds.28912","volume":"37","author":"I Martinez-Valbuena","year":"2022","unstructured":"Martinez-Valbuena I, et al. Combining Skin \u03b1-Synuclein Real-Time Quaking-Induced Conversion and Circulating Neurofilament Light Chain to Distinguish Multiple System Atrophy and Parkinson\u2019s Disease. Mov Disord. 2022;37(3):648\u201350.","journal-title":"Mov Disord"},{"issue":"7794","key":"1488_CR21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41586-020-1984-7","volume":"578","author":"M Shahnawaz","year":"2020","unstructured":"Shahnawaz M, et al. Discriminating \u03b1-synuclein strains in Parkinson\u2019s disease and multiple system atrophy. Nature. 2020;578(7794):273\u20137.","journal-title":"Nature"},{"issue":"2","key":"1488_CR22","doi-asserted-by":"publisher","first-page":"fcaa142","DOI":"10.1093\/braincomms\/fcaa142","volume":"2","author":"C Scial\u00f2","year":"2020","unstructured":"Scial\u00f2 C, et al. TDP-43 real-time quaking induced conversion reaction optimization and detection of seeding activity in CSF of amyotrophic lateral sclerosis and frontotemporal dementia patients. Brain Commun. 2020;2(2):fcaa142.","journal-title":"Brain Commun"},{"issue":"8","key":"1488_CR23","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack","year":"2024","unstructured":"Jack CR, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. 2024;20(8):5143\u201369.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"1488_CR24","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/ana.25811","volume":"88","author":"DJ Irwin","year":"2020","unstructured":"Irwin DJ, et al. Evolution of Alzheimer\u2019s Disease Cerebrospinal Fluid Biomarkers in Early Parkinson\u2019s Disease. Ann Neurol. 2020;88(3):574\u201387.","journal-title":"Ann Neurol"},{"issue":"1","key":"1488_CR25","doi-asserted-by":"publisher","first-page":"14820","DOI":"10.1038\/s41598-021-94345-8","volume":"11","author":"MS Baek","year":"2021","unstructured":"Baek MS, et al. Temporal trajectory of biofluid markers in Parkinson\u2019s disease. Sci Rep. 2021;11(1):14820.","journal-title":"Sci Rep"},{"issue":"4","key":"1488_CR26","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s13760-023-02251-9","volume":"123","author":"F Nabizadeh","year":"2023","unstructured":"Nabizadeh, F., Sodeifian, F., & Kargar, A. (2023). Cerebrospinal fluid alpha-synuclein, amyloid beta, total tau, and phosphorylated tau in tremor-dominant Parkinson\u2019s disease. Acta Neurologica Belgica, 123(4), 1429\u201337.","journal-title":"Acta Neurologica Belgica"},{"issue":"12","key":"1488_CR27","doi-asserted-by":"publisher","first-page":"7537","DOI":"10.1007\/s00415-024-12669-7","volume":"271","author":"A Pilotto","year":"2024","unstructured":"Pilotto A, et al. Plasma NfL, GFAP, amyloid, and p-tau species as Prognostic biomarkers in Parkinson\u2019s disease. J Neurol. 2024;271(12):7537\u201346.","journal-title":"J Neurol"},{"issue":"2","key":"1488_CR28","doi-asserted-by":"publisher","first-page":"fcac040","DOI":"10.1093\/braincomms\/fcac040","volume":"4","author":"D B\u00e4ckstr\u00f6m","year":"2022","unstructured":"B\u00e4ckstr\u00f6m D, et al. Prediction and early biomarkers of cognitive decline in Parkinson disease and atypical parkinsonism: a population-based study. Brain Commun. 2022;4(2):fcac040.","journal-title":"Brain Commun"},{"issue":"1","key":"1488_CR29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1159\/000534552","volume":"13","author":"Z Tufekcioglu","year":"2023","unstructured":"Tufekcioglu Z, et al. Cognitive Profile in Parkinson\u2019s Disease Dementia Patients with Low versus Normal Cerebrospinal Fluid Amyloid Beta. Dement Geriatr Cogn Dis Extra. 2023;13(1):39\u201347.","journal-title":"Dement Geriatr Cogn Dis Extra"},{"key":"1488_CR30","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3389\/fnagi.2020.00112","volume":"12","author":"NC Chen","year":"2020","unstructured":"Chen NC, et al. Plasma Levels of \u03b1-Synuclein, A\u03b2-40 and T-tau as Biomarkers to Predict Cognitive Impairment in Parkinson\u2019s Disease. Front Aging Neurosci. 2020;12:112.","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"1488_CR31","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s41531-021-00247-x","volume":"7","author":"JM Hatcher-Martin","year":"2021","unstructured":"Hatcher-Martin JM, et al. Cerebrospinal fluid biomarkers in Parkinson\u2019s disease with freezing of gait: an exploratory analysis. NPJ Parkinsons Dis. 2021;7(1):105.","journal-title":"NPJ Parkinsons Dis"},{"issue":"1","key":"1488_CR32","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41531-022-00384-x","volume":"8","author":"L Batzu","year":"2022","unstructured":"Batzu L, et al. Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson\u2019s disease. NPJ Parkinsons Dis. 2022;8(1):154.","journal-title":"NPJ Parkinsons Dis"},{"issue":"3","key":"1488_CR33","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1002\/mds.28370","volume":"36","author":"S Hall","year":"2021","unstructured":"Hall S, et al. Plasma Phospho-Tau Identifies Alzheimer\u2019s Co-Pathology in Patients with Lewy Body Disease. Mov Disord. 2021;36(3):767\u201371.","journal-title":"Mov Disord"},{"key":"1488_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/mds.30238","author":"R Ye","year":"2025","unstructured":"Ye, R., et al. (2025). Plasma phosphorylated Tau181 as a biomarker for Alzheimer\u2019s disease co-pathology in Lewy body disease. Movement Disorders. https:\/\/doi.org\/10.1002\/mds.30238","journal-title":"Movement Disorders"},{"issue":"5","key":"1488_CR35","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/acn3.51768","volume":"10","author":"KAQ Cousins","year":"2023","unstructured":"Cousins KAQ, et al. Plasma GFAP associates with secondary Alzheimer\u2019s pathology in Lewy body disease. Ann Clin Transl Neurol. 2023;10(5):802\u201313.","journal-title":"Ann Clin Transl Neurol"},{"issue":"3","key":"1488_CR36","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1002\/ana.27003","volume":"96","author":"C Abdelnour","year":"2024","unstructured":"Abdelnour C, et al. Plasma pTau181 Reveals a Pathological Signature that Predicts Cognitive Outcomes in Lewy Body Disease. Ann Neurol. 2024;96(3):526\u201338.","journal-title":"Ann Neurol"},{"issue":"1","key":"1488_CR37","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13195-024-01502-y","volume":"16","author":"A Vrillon","year":"2024","unstructured":"Vrillon A, et al. Plasma biomarkers of amyloid, tau, axonal, and neuroinflammation pathologies in dementia with Lewy bodies. Alzheimers Res Ther. 2024;16(1):146.","journal-title":"Alzheimers Res Ther"},{"key":"1488_CR38","doi-asserted-by":"crossref","unstructured":"Kwon EH et al. Update on CSF Biomarkers in Parkinson\u2019s Disease. Biomolecules, 2022. 12(2). https:\/\/www.mdpi.com\/2218-273X\/12\/2\/329","DOI":"10.3390\/biom12020329"},{"key":"1488_CR39","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.parkreldis.2022.05.022","volume":"100","author":"IM Walker","year":"2022","unstructured":"Walker IM, et al. Non-tremor motor dysfunction in Lewy body dementias is associated with AD biomarkers. Parkinsonism Relat Disord. 2022;100:33\u20136.","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"1488_CR40","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/ane.13517","volume":"145","author":"WT Lin","year":"2022","unstructured":"Lin WT, et al. Plasma total tau predicts executive dysfunction in Parkinson\u2019s disease. Acta Neurol Scand. 2022;145(1):30\u20137.","journal-title":"Acta Neurol Scand"},{"issue":"12","key":"1488_CR41","doi-asserted-by":"publisher","first-page":"e209418","DOI":"10.1212\/WNL.0000000000209418","volume":"102","author":"K Bolsewig","year":"2024","unstructured":"Bolsewig, K., et al. (2024). Association of plasma amyloid, P-Tau, GFAP, and NfL with CSF, clinical, and cognitive features in patients with dementia with Lewy bodies. Neurology, 102(12), e209418.","journal-title":"Neurology"},{"issue":"1","key":"1488_CR42","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1001\/jamaneurol.2021.4222","volume":"79","author":"MC Gonzalez","year":"2022","unstructured":"Gonzalez MC, et al. Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies. JAMA Neurol. 2022;79(1):32\u20137.","journal-title":"JAMA Neurol"},{"issue":"6","key":"1488_CR43","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1093\/brain\/awaf003","volume":"148","author":"A Delva","year":"2025","unstructured":"Delva A, et al. Plasma pTau181 and amyloid markers predict conversion to dementia in idiopathic REM sleep behaviour disorder. Brain. 2025;148(6):2049\u201359.","journal-title":"Brain"},{"issue":"4","key":"1488_CR44","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1001\/jamaneurol.2024.5017","volume":"82","author":"L VandeVrede","year":"2025","unstructured":"VandeVrede L, et al. Detection of Alzheimer Neuropathology in Alzheimer and Non-Alzheimer Clinical Syndromes With Blood-Based Biomarkers. JAMA Neurol. 2025;82(4):344\u201354.","journal-title":"JAMA Neurol"},{"issue":"2","key":"1488_CR45","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/jnc.15944","volume":"167","author":"D Kon\u00ed\u010dkov\u00e1","year":"2023","unstructured":"Kon\u00ed\u010dkov\u00e1 D, et al. Cerebrospinal fluid and blood serum biomarkers in neurodegenerative proteinopathies: A prospective, open, cross-correlation study. J Neurochem. 2023;167(2):168\u201382.","journal-title":"J Neurochem"},{"key":"1488_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25136882","author":"CM Cristiani","year":"2024","unstructured":"Cristiani, C. M., et al. (2024). Serum oligomeric \u03b1-synuclein and p-tau181 in progressive supranuclear palsy and Parkinson\u2019s disease. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms25136882","journal-title":"International Journal of Molecular Sciences"},{"issue":"12","key":"1488_CR47","doi-asserted-by":"publisher","first-page":"e209460","DOI":"10.1212\/WNL.0000000000209460","volume":"102","author":"R Ye","year":"2024","unstructured":"Ye, R., et al. (2024). Differential vulnerability of hippocampal subfields to amyloid and tau deposition in the Lewy body diseases. Neurology, 102(12), e209460.","journal-title":"Neurology"},{"issue":"5","key":"1488_CR48","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1093\/brain\/awae352","volume":"148","author":"MT Duong","year":"2025","unstructured":"Duong MT, et al. Hypometabolic mismatch with atrophy and tau pathology in mixed Alzheimer\u2019s and Lewy body disease. Brain. 2025;148(5):1577\u201387.","journal-title":"Brain"},{"issue":"6","key":"1488_CR49","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1177\/0004867419885165","volume":"54","author":"SJ Colloby","year":"2020","unstructured":"Colloby SJ, et al. Cortical thinning in dementia with Lewy bodies and Parkinson disease dementia. Aust N Z J Psychiatry. 2020;54(6):633\u201343.","journal-title":"Aust N Z J Psychiatry"},{"issue":"7","key":"1488_CR50","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1093\/brain\/awaf037","volume":"148","author":"J Silva-Rodr\u00edguez","year":"2025","unstructured":"Silva-Rodr\u00edguez J, et al. The effect of Lewy body (co-)pathology on the clinical and imaging phenotype of amnestic patients. Brain. 2025;148(7):2441\u201352.","journal-title":"Brain"},{"issue":"5","key":"1488_CR51","doi-asserted-by":"publisher","first-page":"fcae290","DOI":"10.1093\/braincomms\/fcae290","volume":"6","author":"A Rennie","year":"2024","unstructured":"Rennie A, et al. Cerebrovascular and Alzheimer\u2019s disease biomarkers in dementia with Lewy bodies and other dementias. Brain Commun. 2024;6(5):fcae290.","journal-title":"Brain Commun"},{"issue":"5","key":"1488_CR52","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/neup.12745","volume":"41","author":"T Ando","year":"2021","unstructured":"Ando T, et al. The hot cross bun sign in corticobasal degeneration. Neuropathology. 2021;41(5):376\u201380.","journal-title":"Neuropathology"},{"key":"1488_CR53","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.parkreldis.2022.06.008","volume":"101","author":"AF Carlos","year":"2022","unstructured":"Carlos AF, et al. Tau-PET and multimodal imaging in clinically atypical multiple system atrophy masquerading as progressive supranuclear palsy. Parkinsonism Relat Disord. 2022;101:9\u201314.","journal-title":"Parkinsonism Relat Disord"},{"key":"1488_CR54","unstructured":"Pichet Binette A, et al. Evaluation of the Revised Criteria for Biological and Clinical Staging of Alzheimer Disease. JAMA Neurol; 2025. https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2833818"},{"issue":"5","key":"1488_CR55","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1093\/brain\/awae372","volume":"148","author":"SJ Colloby","year":"2025","unstructured":"Colloby SJ, et al. Patterns of tau, amyloid and synuclein pathology in ageing, Alzheimer\u2019s disease and synucleinopathies. Brain. 2025;148(5):1562\u201376.","journal-title":"Brain"},{"issue":"5","key":"1488_CR56","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jagp.2019.12.009","volume":"28","author":"PC Donaghy","year":"2020","unstructured":"Donaghy PC, et al. Amyloid Imaging and Longitudinal Clinical Progression in Dementia With Lewy Bodies. Am J Geriatr Psychiatry. 2020;28(5):573\u20137.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"7","key":"1488_CR57","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/mds.26191","volume":"30","author":"M Petrou","year":"2015","unstructured":"Petrou M, et al. Amyloid deposition in Parkinson\u2019s disease and cognitive impairment: a systematic review. Mov Disord. 2015;30(7):928\u201335.","journal-title":"Mov Disord"},{"issue":"1","key":"1488_CR58","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13041-022-00964-1","volume":"15","author":"AS Mihaescu","year":"2022","unstructured":"Mihaescu AS, et al. Beta amyloid deposition and cognitive decline in Parkinson\u2019s disease: a study of the PPMI cohort. Mol Brain. 2022;15(1):79.","journal-title":"Mol Brain"},{"issue":"10","key":"1488_CR59","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/jnen\/nlw070","volume":"75","author":"DH Hepp","year":"2016","unstructured":"Hepp DH, et al. Distribution and Load of Amyloid-\u03b2 Pathology in Parkinson Disease and Dementia with Lewy Bodies. J Neuropathol Exp Neurol. 2016;75(10):936\u201345.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"21","key":"1488_CR60","doi-asserted-by":"publisher","first-page":"e39194","DOI":"10.1016\/j.heliyon.2024.e39194","volume":"10","author":"L Chen","year":"2024","unstructured":"Chen L, et al. Unraveling the interplay of \u03b2-amyloid pathology and Parkinson\u2019s disease progression: Insights from autopsy-confirmed patients. Heliyon. 2024;10(21):e39194.","journal-title":"Heliyon"},{"issue":"1","key":"1488_CR61","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41531-025-00944-x","volume":"11","author":"E Mak","year":"2025","unstructured":"Mak E, et al. Cortical microstructural abnormalities in dementia with Lewy bodies and their associations with Alzheimer\u2019s disease copathologies. NPJ Parkinsons Dis. 2025;11(1):124.","journal-title":"NPJ Parkinsons Dis"},{"key":"1488_CR62","doi-asserted-by":"publisher","first-page":"107255","DOI":"10.1016\/j.parkreldis.2024.107255","volume":"131","author":"JH Tan","year":"2025","unstructured":"Tan JH, et al. The effect of Amyloid and Tau Co-pathology on disease progression in Lewy body dementia: A systematic review. Parkinsonism Relat Disord. 2025;131:107255.","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"1488_CR63","doi-asserted-by":"publisher","first-page":"e70098","DOI":"10.1002\/trc2.70098","volume":"11","author":"JL Cummings","year":"2025","unstructured":"Cummings JL, et al. Alzheimer\u2019s disease drug development pipeline: 2025. Alzheimers Dement (N Y). 2025;11(2):e70098.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"1\u20132","key":"1488_CR64","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0006-8993(99)01848-X","volume":"843","author":"K Arima","year":"1999","unstructured":"Arima K, et al. Cellular co-localization of phosphorylated tau- and NACP\/alpha-synuclein-epitopes in lewy bodies in sporadic Parkinson\u2019s disease and in dementia with Lewy bodies. Brain Res. 1999;843(1\u20132):53\u201361.","journal-title":"Brain Res"},{"issue":"4","key":"1488_CR65","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1093\/jnen\/62.4.389","volume":"62","author":"T Ishizawa","year":"2003","unstructured":"Ishizawa T, et al. Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol. 2003;62(4):389\u201397.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"1488_CR66","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00415-024-12856-6","volume":"272","author":"F Xu","year":"2024","unstructured":"Xu F, et al. Cerebrospinal fluid tau and disease progression in early Parkinson\u2019s disease: an 8-year longitudinal study. J Neurol. 2024;272(1):61.","journal-title":"J Neurol"},{"key":"1488_CR67","doi-asserted-by":"crossref","unstructured":"Wang Z, et al. Seeding Activity of Skin Misfolded Tau as a Biomarker for Tauopathies. Res Sq; 2024. https:\/\/www.researchsquare.com\/article\/rs-3968879\/v1","DOI":"10.1186\/s13024-024-00781-1"},{"issue":"1","key":"1488_CR68","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41531-024-00728-9","volume":"10","author":"IL Dellarole","year":"2024","unstructured":"Dellarole IL, et al. Tau seeding activity in skin biopsy differentiates tauopathies from synucleinopathies. NPJ Parkinsons Dis. 2024;10(1):116.","journal-title":"NPJ Parkinsons Dis"},{"issue":"2","key":"1488_CR69","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1093\/brain\/awad388","volume":"147","author":"Y Chu","year":"2024","unstructured":"Chu Y, et al. Nigrostriatal tau pathology in parkinsonism and Parkinson\u2019s disease. Brain. 2024;147(2):444\u201357.","journal-title":"Brain"},{"issue":"2","key":"1488_CR70","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.pathol.2024.10.006","volume":"57","author":"SL Forrest","year":"2025","unstructured":"Forrest SL, Kovacs GG. Current concepts and molecular pathology of neurodegenerative diseases. Pathology. 2025;57(2):178\u201390.","journal-title":"Pathology"},{"key":"1488_CR71","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaf135","author":"B Couto","year":"2025","unstructured":"Couto, B., et al. (2025). Midbrain cytotoxic T cells as a distinct neuropathological feature of progressive supranuclear palsy. Brain. https:\/\/doi.org\/10.1093\/brain\/awaf135","journal-title":"Brain"},{"issue":"9","key":"1488_CR72","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1136\/jnnp-2021-328586","volume":"93","author":"S Koga","year":"2022","unstructured":"Koga S, et al. Neuropathology and emerging biomarkers in corticobasal syndrome. J Neurol Neurosurg Psychiatry. 2022;93(9):919\u201329.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"1488_CR73","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1093\/brain\/awy146","volume":"141","author":"JL Robinson","year":"2018","unstructured":"Robinson JL, et al. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain. 2018;141(7):2181\u201393.","journal-title":"Brain"},{"key":"1488_CR74","doi-asserted-by":"crossref","unstructured":"Aiba I et al. Clinical course of pathologically confirmed corticobasal degeneration and corticobasal syndrome. Brain Commun, 2023. 5(6). https:\/\/academic.oup.com\/braincomms\/article\/5\/6\/fcad296\/7341983","DOI":"10.1093\/braincomms\/fcae028"},{"issue":"3\u20134","key":"1488_CR75","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1080\/21678421.2020.1733019","volume":"21","author":"C Pennington","year":"2020","unstructured":"Pennington C, et al. Mixed neuropathology in frontotemporal lobar degeneration. Amyotroph Lateral Scler Frontotemporal Degeneration. 2020;21(3\u20134):301\u20138.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degeneration"},{"key":"1488_CR76","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-024-02716-y","author":"C Maldonado-D\u00edaz","year":"2024","unstructured":"Maldonado-D\u00edaz, C., et al. (2024). Disentangling and quantifying the relative cognitive impact of concurrent mixed neurodegenerative pathologies. Acta Neuropathologica. https:\/\/doi.org\/10.1007\/s00401-024-02716-y","journal-title":"Acta Neuropathologica"},{"issue":"8","key":"1488_CR77","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1093\/brain\/awac091","volume":"145","author":"Y Riku","year":"2022","unstructured":"Riku Y, et al. Motor neuron TDP-43 proteinopathy in progressive supranuclear palsy and corticobasal degeneration. Brain. 2022;145(8):2769\u201384.","journal-title":"Brain"},{"issue":"5","key":"1488_CR78","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.3390\/ijms25052740","volume":"25","author":"M Mimuro","year":"2024","unstructured":"Mimuro M, Iwasaki Y. Age-Related Pathology in Corticobasal Degeneration. Int J Mol Sci. 2024;25(5):2740.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1488_CR79","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1002\/ana.25893","volume":"88","author":"A Ghirelli","year":"2020","unstructured":"Ghirelli A, et al. Sensitivity\u2013Specificity of Tau and Amyloid \u03b2 Positron Emission Tomography in Frontotemporal Lobar Degeneration. Ann Neurol. 2020;88(5):1009\u201322.","journal-title":"Ann Neurol"},{"issue":"1","key":"1488_CR80","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1212\/WNL.0000000000009734","volume":"95","author":"N Sakae","year":"2020","unstructured":"Sakae N, et al. Clinical and pathologic features of cognitive-predominant corticobasal degeneration. Neurology. 2020;95(1):e35\u201345.","journal-title":"Neurology"},{"issue":"3","key":"1488_CR81","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1093\/jnen\/nlae134","volume":"84","author":"S Hiya","year":"2025","unstructured":"Hiya S, et al. Unraveling the clinical\u2013pathological correlations of subjects with isolated and mixed neurodegenerative processes in the National Alzheimer\u2019s Coordinating Center dataset. J Neuropathology Experimental Neurol. 2025;84(3):177\u201394.","journal-title":"J Neuropathology Experimental Neurol"},{"issue":"3","key":"1488_CR82","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1093\/jnen\/nlz141","volume":"79","author":"JL Robinson","year":"2020","unstructured":"Robinson JL, et al. Primary Tau Pathology, Not Copathology, Correlates With Clinical Symptoms in PSP and CBD. J Neuropathology Experimental Neurol. 2020;79(3):296\u2013304.","journal-title":"J Neuropathology Experimental Neurol"},{"issue":"4","key":"1488_CR83","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00401-019-02119-4","volume":"139","author":"H Ling","year":"2020","unstructured":"Ling H, et al. Fulminant corticobasal degeneration: a distinct variant with predominant neuronal tau aggregates. Acta Neuropathol. 2020;139(4):717\u201334.","journal-title":"Acta Neuropathol"},{"issue":"6","key":"1488_CR84","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/mds.28011","volume":"35","author":"M Jecmenica Lukic","year":"2020","unstructured":"Jecmenica Lukic, M., et al. (2020). Copathology in Progressive Supranuclear Palsy: Does It Matter? Movement Disorders, 35(6), 984\u2013993.","journal-title":"Movement Disorders"},{"issue":"5","key":"1488_CR85","doi-asserted-by":"publisher","first-page":"e70248","DOI":"10.1002\/alz.70248","volume":"21","author":"T Popli","year":"2025","unstructured":"Popli T, et al. High rates of diagnostic discordance and co-pathology: Insights into PSP from the NACC dataset. Alzheimers Dement. 2025;21(5):e70248.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"1488_CR86","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/mds.870120203","volume":"12","author":"GK Wenning","year":"1997","unstructured":"Wenning GK, et al. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord. 1997;12(2):133\u201347.","journal-title":"Mov Disord"},{"issue":"7","key":"1488_CR87","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s00702-020-02201-2","volume":"127","author":"KA Jellinger","year":"2020","unstructured":"Jellinger, K. A. (2020). Neuropathological findings in multiple system atrophy with cognitive impairment. Journal of Neural Transmission (Vienna), 127(7), 1031\u20139.","journal-title":"Journal of Neural Transmission (Vienna)"},{"issue":"21","key":"1488_CR88","doi-asserted-by":"publisher","first-page":"e2472","DOI":"10.1212\/WNL.0000000000007530","volume":"92","author":"SL Forrest","year":"2019","unstructured":"Forrest SL, et al. Coexisting Lewy body disease and clinical parkinsonism in frontotemporal lobar degeneration. Neurology. 2019;92(21):e2472\u201382.","journal-title":"Neurology"},{"issue":"3","key":"1488_CR89","doi-asserted-by":"publisher","first-page":"fcae141","DOI":"10.1093\/braincomms\/fcae141","volume":"6","author":"T Kon","year":"2024","unstructured":"Kon T, et al. Multiple system atrophy with amyloid-\u03b2-predominant Alzheimer\u2019s disease neuropathologic change. Brain Commun. 2024;6(3):fcae141.","journal-title":"Brain Commun"},{"issue":"Pt 12","key":"1488_CR90","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1093\/brain\/awh303","volume":"127","author":"T Ozawa","year":"2004","unstructured":"Ozawa T, et al. The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain. 2004;127(Pt 12):2657\u201371.","journal-title":"Brain"},{"issue":"11","key":"1488_CR91","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1136\/jnnp.2009.182576","volume":"81","author":"T Ozawa","year":"2010","unstructured":"Ozawa T, et al. The phenotype spectrum of Japanese multiple system atrophy. J Neurol Neurosurg Psychiatry. 2010;81(11):1253\u20135.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"1488_CR92","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2183\/pjab.93.016","volume":"93","author":"T Ozawa","year":"2017","unstructured":"Ozawa, T., & Onodera, O. (2017). Multiple system atrophy: Clinicopathological characteristics in Japanese patients. Proceedings of the Japan Academy. Series B, Physical and Biological Sciences, 93(5), 251\u20138.","journal-title":"Proceedings of the Japan Academy. Series B, Physical and Biological Sciences"},{"issue":"4","key":"1488_CR93","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s00401-006-0192-3","volume":"113","author":"B Terni","year":"2007","unstructured":"Terni B, et al. Mutant ubiquitin and p62 immunoreactivity in cases of combined multiple system atrophy and Alzheimer\u2019s disease. Acta Neuropathol. 2007;113(4):403\u201316.","journal-title":"Acta Neuropathol"},{"key":"1488_CR94","unstructured":"Couto B et al. The Rossy Progressive Supranuclear Palsy Centre: Creation and Initial Experience. Can J Neurol Sci, 2023: pp. 1\u20138. https:\/\/www.cambridge.org\/core\/product\/identifier\/S0317167122003328\/type\/journal_article"},{"key":"1488_CR95","doi-asserted-by":"publisher","first-page":"105296","DOI":"10.1016\/j.parkreldis.2023.105296","volume":"108","author":"SY Lim","year":"2023","unstructured":"Lim SY, et al. New insights from a multi-ethnic Asian progressive supranuclear palsy cohort. Parkinsonism Relat Disord. 2023;108:105296.","journal-title":"Parkinsonism Relat Disord"},{"key":"1488_CR96","doi-asserted-by":"crossref","unstructured":"Lim SY, et al. Differences in progressive supranuclear palsy in patients of Asian ancestry? Parkinsonism Relat Disord; 2024. p. 107162. https:\/\/pubmed.ncbi.nlm.nih.gov\/39406616\/","DOI":"10.1016\/j.parkreldis.2024.107162"},{"key":"1488_CR97","first-page":"100339","volume":"12","author":"MJ Angel","year":"2025","unstructured":"Angel MJ, et al. Prospective longitudinal cohort of Argentinean patients with progressive supranuclear palsy and corticobasal syndrome: A platform for epidemiological and translational research. Clin Park Relat Disord. 2025;12:100339.","journal-title":"Clin Park Relat Disord"},{"key":"1488_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.107179","volume":"130","author":"B Couto","year":"2025","unstructured":"Couto, B., et al. (2025). Differences in progressive supranuclear palsy in patients of Asian ancestry? Parkinsonism & Related Disorders, 130, Article 107179.","journal-title":"Parkinsonism & Related Disorders"},{"issue":"25","key":"1488_CR99","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1021\/acs.biochem.9b00215","volume":"58","author":"AKR Dasari","year":"2019","unstructured":"Dasari AKR, et al. Tau Interacts with the C-Terminal Region of \u03b1-Synuclein, Promoting Formation of Toxic Aggregates with Distinct Molecular Conformations. Biochemistry. 2019;58(25):2814\u201321.","journal-title":"Biochemistry"},{"issue":"5","key":"1488_CR100","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nm1746","volume":"14","author":"JY Li","year":"2008","unstructured":"Li JY, et al. Lewy bodies in grafted neurons in subjects with Parkinson\u2019s disease suggest host-to-graft disease propagation. Nat Med. 2008;14(5):501\u20133.","journal-title":"Nat Med"},{"issue":"5","key":"1488_CR101","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/nm1747","volume":"14","author":"JH Kordower","year":"2008","unstructured":"Kordower JH, et al. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson\u2019s disease. Nat Med. 2008;14(5):504\u20136.","journal-title":"Nat Med"},{"issue":"10","key":"1488_CR102","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJM200103083441002","volume":"344","author":"CR Freed","year":"2001","unstructured":"Freed CR, et al. Transplantation of embryonic dopamine neurons for severe Parkinson\u2019s disease. N Engl J Med. 2001;344(10):710\u20139.","journal-title":"N Engl J Med"},{"issue":"45","key":"1488_CR103","doi-asserted-by":"publisher","first-page":"9754","DOI":"10.1523\/JNEUROSCI.0344-18.2018","volume":"38","author":"PJ Teravskis","year":"2018","unstructured":"Teravskis PJ, et al. A53T Mutant Alpha-Synuclein Induces Tau-Dependent Postsynaptic Impairment Independently of Neurodegenerative Changes. J Neurosci. 2018;38(45):9754\u201367.","journal-title":"J Neurosci"},{"issue":"9","key":"1488_CR104","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1111\/ejn.14699","volume":"53","author":"ST Feng","year":"2021","unstructured":"Feng ST, et al. Update on the association between alpha-synuclein and tau with mitochondrial dysfunction: Implications for Parkinson\u2019s disease. Eur J Neurosci. 2021;53(9):2946\u201359.","journal-title":"Eur J Neurosci"},{"key":"1488_CR105","doi-asserted-by":"publisher","first-page":"1189809","DOI":"10.3389\/fnagi.2023.1189809","volume":"15","author":"Y Han","year":"2023","unstructured":"Han Y, He Z. Concomitant protein pathogenesis in Parkinson\u2019s disease and perspective mechanisms. Front Aging Neurosci. 2023;15:1189809.","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"1488_CR106","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13024-024-00782-0","volume":"19","author":"S Greally","year":"2024","unstructured":"Greally S, et al. Dementia with lewy bodies patients with high tau levels display unique proteome profiles. Mol Neurodegener. 2024;19(1):98.","journal-title":"Mol Neurodegener"},{"key":"1488_CR107","doi-asserted-by":"publisher","first-page":"107874","DOI":"10.1016\/j.parkreldis.2025.107874","volume":"136","author":"AJ Espay","year":"2025","unstructured":"Espay AJ, et al. Alpha-synuclein in Parkinson\u2019s disease: Embracing debate, exercising skepticism. Parkinsonism Relat Disord. 2025;136:107874.","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"1488_CR108","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41419-023-05672-9","volume":"14","author":"P Calabresi","year":"2023","unstructured":"Calabresi P, et al. Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis. 2023;14(3):176.","journal-title":"Cell Death Dis"},{"key":"1488_CR109","doi-asserted-by":"publisher","DOI":"10.1002\/mds.30269","author":"AJ Espay","year":"2025","unstructured":"Espay, A. J., et al. (2025). Refutation of the \u03b1Syn-SAA-based staging for Parkinson\u2019s progression (Neuronal \u03b1-Synuclein Disease-Integrated Staging System [NSD-ISS]). Movement Disorders. https:\/\/doi.org\/10.1002\/mds.30269","journal-title":"Movement Disorders"},{"issue":"12","key":"1488_CR110","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1002\/mds.30019","volume":"39","author":"DP Vaughan","year":"2024","unstructured":"Vaughan DP, et al. Evaluation of Cerebrospinal Fluid \u03b1-Synuclein Seed Amplification Assay in Progressive Supranuclear Palsy and Corticobasal Syndrome. Mov Disord. 2024;39(12):2285\u201391.","journal-title":"Mov Disord"},{"issue":"6","key":"1488_CR111","doi-asserted-by":"publisher","first-page":"e209818","DOI":"10.1212\/WNL.0000000000209818","volume":"103","author":"C Anastassiadis","year":"2024","unstructured":"Anastassiadis C, et al. CSF \u03b1-Synuclein Seed Amplification Assay in Patients With Atypical Parkinsonian Disorders. Neurology. 2024;103(6):e209818.","journal-title":"Neurology"},{"issue":"9","key":"1488_CR112","doi-asserted-by":"publisher","first-page":"e209884","DOI":"10.1212\/WNL.0000000000209884","volume":"103","author":"J Hazan","year":"2024","unstructured":"Hazan J, et al. Challenges in a Biological Definition of Alzheimer Disease. Neurology. 2024;103(9):e209884.","journal-title":"Neurology"},{"issue":"4","key":"1488_CR113","doi-asserted-by":"publisher","first-page":"100102","DOI":"10.1016\/j.tjpad.2025.100102","volume":"12","author":"J Rosen","year":"2025","unstructured":"Rosen, J., & Jessen, F. (2025). Patient eligibility for amyloid-targeting immunotherapies in Alzheimer\u2019s disease. Journal of Prevention of Alzheimer\u2019s Disease, 12(4), 100102.","journal-title":"Journal of Prevention of Alzheimer's Disease"},{"key":"1488_CR114","doi-asserted-by":"publisher","first-page":"117010","DOI":"10.1016\/j.jns.2020.117010","volume":"416","author":"T Homma","year":"2020","unstructured":"Homma T, et al. Cerebral white matter tau-positive granular glial pathology as a characteristic pathological feature in long survivors of multiple system atrophy. J Neurol Sci. 2020;416:117010.","journal-title":"J Neurol Sci"},{"issue":"8","key":"1488_CR115","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1111\/ene.15346","volume":"29","author":"B Couto","year":"2022","unstructured":"Couto B, et al. Protracted course progressive supranuclear palsy. Eur J Neurol. 2022;29(8):2220\u201331.","journal-title":"Eur J Neurol"},{"issue":"4","key":"1488_CR116","doi-asserted-by":"publisher","first-page":"330","DOI":"10.2174\/1567205019666220308152219","volume":"19","author":"RP Coburn","year":"2022","unstructured":"Coburn RP, et al. Dysexecutive Alzheimer\u2019s Disease with Lewy Body Disease Co-Pathology. Curr Alzheimer Res. 2022;19(4):330\u20133.","journal-title":"Curr Alzheimer Res"},{"issue":"4","key":"1488_CR117","doi-asserted-by":"publisher","first-page":"e13000","DOI":"10.1111\/nan.13000","volume":"50","author":"H Tanaka","year":"2024","unstructured":"Tanaka H, et al. Ageing-related tau astrogliopathy severely affecting the substantia nigra. Neuropathol Appl Neurobiol. 2024;50(4):e13000.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"1","key":"1488_CR118","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/neup.12779","volume":"42","author":"T Homma","year":"2022","unstructured":"Homma, T., et al. (2022). Tufted astrocyte-like glia in two autopsy cases of multiple system atrophy: Is it a concomitant neurodegenerative disorder with multiple system atrophy and progressive supranuclear palsy? Neuropathology, 42(1), 74\u201381.","journal-title":"Neuropathology"},{"issue":"11","key":"1488_CR119","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1002\/mds.28308","volume":"35","author":"G Videira","year":"2020","unstructured":"Videira G, et al. Letter to the Editor on Copathology in Progressive Supranuclear Palsy: Does It Matter? Mov Disord. 2020;35(11):2124\u20136.","journal-title":"Mov Disord"},{"issue":"1","key":"1488_CR120","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12974-023-02843-5","volume":"20","author":"T Liu","year":"2023","unstructured":"Liu T, et al. Cerebrospinal fluid GFAP is a predictive biomarker for conversion to dementia and Alzheimer\u2019s disease-associated biomarkers alterations among de novo Parkinson\u2019s disease patients: a prospective cohort study. J Neuroinflammation. 2023;20(1):167.","journal-title":"J Neuroinflammation"},{"key":"1488_CR121","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-025-02013-z","author":"C Kurz","year":"2025","unstructured":"Kurz, C., et al. (2025). Plasma biomarkers of amyloid, tau & neuroinflammation in Alzheimer\u2019s disease and corticobasal syndrome. European Archives of Psychiatry and Clinical Neuroscience. https:\/\/doi.org\/10.1007\/s00406-025-02013-z","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"issue":"17","key":"1488_CR122","doi-asserted-by":"publisher","first-page":"e1708","DOI":"10.1212\/WNL.0000000000207755","volume":"101","author":"JJ Alam","year":"2023","unstructured":"Alam, J. J., et al. (2023). Association of plasma phosphorylated tau with the response to neflamapimod treatment in patients with dementia with Lewy bodies. Neurology, 101(17), e1708-17.","journal-title":"Neurology"},{"issue":"4","key":"1488_CR123","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1002\/alz.13653","volume":"20","author":"P Diaz-Galvan","year":"2024","unstructured":"Diaz-Galvan P, et al. Plasma biomarkers of Alzheimer\u2019s disease in the continuum of dementia with Lewy bodies. Alzheimers Dement. 2024;20(4):2485\u201396.","journal-title":"Alzheimers Dement"},{"key":"1488_CR124","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.parkreldis.2022.07.008","volume":"101","author":"PC Donaghy","year":"2022","unstructured":"Donaghy PC, et al. The relationship between plasma biomarkers and amyloid PET in dementia with Lewy bodies. Parkinsonism Relat Disord. 2022;101:111\u20136.","journal-title":"Parkinsonism Relat Disord"},{"issue":"12","key":"1488_CR125","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/jnen\/nlac094","volume":"81","author":"DG Coughlin","year":"2022","unstructured":"Coughlin DG, et al. Digital Histological Study of Neocortical Grey and White Matter Tau Burden Across Tauopathies. J Neuropathol Exp Neurol. 2022;81(12):953\u201364.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"6","key":"1488_CR126","doi-asserted-by":"publisher","first-page":"100127","DOI":"10.1016\/j.labinv.2023.100127","volume":"103","author":"M Kim","year":"2023","unstructured":"Kim M, et al. Diagnosis of Alzheimer Disease and Tauopathies on Whole-Slide Histopathology Images Using a Weakly Supervised Deep Learning Algorithm. Lab Invest. 2023;103(6):100127.","journal-title":"Lab Invest"},{"issue":"1","key":"1488_CR127","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13024-024-00741-9","volume":"19","author":"J Lantero-Rodriguez","year":"2024","unstructured":"Lantero-Rodriguez J, et al. Tau protein profiling in tauopathies: a human brain study. Mol Neurodegener. 2024;19(1):54.","journal-title":"Mol Neurodegener"},{"issue":"9","key":"1488_CR128","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1136\/jnnp-2023-332862","volume":"95","author":"D Shir","year":"2024","unstructured":"Shir D, et al. Clinicoradiological and neuropathological evaluation of primary progressive aphasia. J Neurol Neurosurg Psychiatry. 2024;95(9):812\u201321.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"1488_CR129","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1093\/brain\/awaa276","volume":"143","author":"DN Soleimani-Meigooni","year":"2020","unstructured":"Soleimani-Meigooni DN, et al. 18F-flortaucipir PET to autopsy comparisons in Alzheimer\u2019s disease and other neurodegenerative diseases. Brain. 2020;143(11):3477\u201394.","journal-title":"Brain"},{"issue":"3","key":"1488_CR130","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/mds.29311","volume":"38","author":"EW Wang","year":"2023","unstructured":"Wang EW, et al. Susceptibility Magnetic Resonance Imaging Correlates with Glial Density and Tau in the Substantia Nigra Pars Compacta. Mov Disord. 2023;38(3):464\u201373.","journal-title":"Mov Disord"},{"issue":"1","key":"1488_CR131","doi-asserted-by":"publisher","first-page":"e14355","DOI":"10.1002\/alz.14355","volume":"21","author":"K Yoshida","year":"2025","unstructured":"Yoshida K, et al. Co-pathologies modify hippocampal protein accumulation patterns in neurodegenerative diseases. Alzheimers Dement. 2025;21(1):e14355.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1488_CR132","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00401-019-02080-2","volume":"139","author":"E Saijo","year":"2020","unstructured":"Saijo E, et al. 4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration. Acta Neuropathol. 2020;139(1):63\u201377.","journal-title":"Acta Neuropathol"},{"key":"1488_CR133","doi-asserted-by":"publisher","first-page":"102196","DOI":"10.1016\/j.nicl.2020.102196","volume":"26","author":"R Ye","year":"2020","unstructured":"Ye R, et al. Topography of cortical thinning in the Lewy body diseases. Neuroimage Clin. 2020;26:102196.","journal-title":"Neuroimage Clin"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-026-01488-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11910-026-01488-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-026-01488-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T09:02:35Z","timestamp":1774429355000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11910-026-01488-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":133,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1488"],"URL":"https:\/\/doi.org\/10.1007\/s11910-026-01488-0","relation":{},"ISSN":["1534-6293"],"issn-type":[{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"1 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}